ResMed Inc., based in San Diego, develops medical devices and software for respiratory disorders, with a market cap of $39.6 billion. RMD is a large-cap stock in the medical instruments & supplies industry.

RMD hit a three-year high in August but currently trades 8.1% below that peak. The stock has outperformed the Health Care Select Sector SPDR Fund over the past three months.

ResMed’s stock prices have surged in 2025, up 18.1%, and 7.8% over the past 52 weeks, outperforming its peers in the industry.

After reporting strong Q4 results, RMD saw a 2.7% increase in stock prices. Its net revenues grew 10.2% year-over-year, surpassing expectations, and non-GAAP EPS increased 22.6%.

ResMed has a consensus “Moderate Buy” rating with a mean price target of $289.25, indicating a 7.1% upside potential from current levels.

Read more at Yahoo Finance: How Is ResMed’s Stock Performance Compared to Other Healthcare Stocks?